Outpatient respiratory syncytial virus infections and novel preventive interventions

Sarah F Hak, Roderick P Venekamp, Joanne G Wildenbeest, Louis J Bont*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Downloads (Pure)


PURPOSE OF REVIEW: With interventions to prevent respiratory syncytial virus (RSV) infection within reach, this review aims to provide healthcare professionals with the latest information necessary to inform parents and assess the potential impact of RSV prevention on everyday practice. We address frequently asked questions for parental counseling.

RECENT FINDINGS: Numerous studies emphasize the major burden of RSV on young children, parents, healthcare and society. In the first year of life, about 14% of healthy term infants visit a doctor and 2% require hospitalization due to RSV. In older children (1--5 years), RSV infections and associated morbidity (wheeze, acute otitis media) are major drivers of outpatient visits. A novel maternal RSV vaccine and long-acting mAb can provide protection during infants' first months of life. This maternal vaccine showed 70.9% efficacy against severe RSV infection within 150 days after birth; the mAb nirsevimab reduces medically attended RSV infections by 79.5% within 150 days after administration. Both gained regulatory approval in the USA (FDA) and Europe (EMA).

SUMMARY: Novel RSV immunizations hold promise to reduce the RSV burden in infants, with substantial impact on everyday practice. Tailored parental guidance will be instrumental for successful implementation. Awaiting pediatric vaccines, RSV infections beyond infancy will still pose a significant outpatient burden.

Original languageEnglish
Pages (from-to)171-181
Number of pages11
JournalCurrent Opinion in Pediatrics
Issue number2
Early online date13 Dec 2023
Publication statusPublished - 1 Apr 2024


  • mAbs
  • maternal immunization
  • outpatient
  • respiratory syncytial virus
  • vaccines


Dive into the research topics of 'Outpatient respiratory syncytial virus infections and novel preventive interventions'. Together they form a unique fingerprint.

Cite this